$FYB (-3,56%) Does anyone know what's going on here? Light at the end of the tunnel?

How do you currently rate $FYB (-3,56%) and $PHIA (+1,57%) ? Is there still hope in the long term?

Hope for US-Chinese rapprochement lives on + Secret revealed: Trump wants to cut drug prices + Evonik confirms annual target + Formycon starts the year with losses

Hope for US-Chinese rapprochement lives on

• Progress in the tariff conflict between the USA and China should ensure a positive mood on Europe's stock markets on Monday.
• The Dax is likely to continue its record-breaking run, which it resumed on Friday after a break of almost two months.
• Wall Street is also expected to be strong, while the start of the week in Asia was rather subdued.
• According to the White House, the USA has reached an agreement with China on the tariff dispute during talks in Geneva.
• No details were initially given. Both sides announced a statement for Monday.
• The Chinese delegation initially only spoke of a "series of important agreements".

Secret revealed: Trump wants to lower prices for medicines

• The big announcement made by US President Donald Trump is now out:
• He wants to lower the prices of prescription drugs and is taking aim at the pharmaceutical industry.
• He will sign one of the "most consequential decrees" in US history on Monday morning (local time), the Republican announced on his online mouthpiece Truth Social.
• He had previously written there that he would be making "one of the most important" announcements ever.
• Trump had already held out the prospect of an "earth-shattering" announcement last week.
• US media had already speculated that it could be about drug prices.
• Drug prices are an important issue in the USA.
• There is currently no central government price regulation that applies to all medicines.
• The pharmaceutical industry plays the most important role in the question of how much a drug costs - government influence is limited.
• This sometimes leads to enormously high prices - in an international comparison, many medicines in the USA are significantly more expensive.
• In Germany, on the other hand, various forms of state regulation take effect.
• Trump promises significant price reduction Trump sees the USA at a disadvantage because of the high prices.
• The world wonders why prescription drugs are so much more expensive in the USA than in other countries around the world, even though they are produced in the same laboratory by the same company, he wrote.
• "It was always hard to explain and very embarrassing because, in truth, there was no real or justifiable explanation." Trump promised that drug prices in the US would fall by 30 to 80 percent "almost immediately".
• "Worldwide, prices will rise to create balance and - for the first time in many years - bring justice to America!"
• Trump wants to ensure that no more is paid for certain prescription drugs in the USA than in other countries.
• It remains to be seen whether this only applies to drugs covered by the state health insurance program for senior citizens (Medicare) - or whether Trump wants to go one step further with price regulation.
• This could be particularly difficult legally - but pharmaceutical companies are likely to oppose the plan anyway.
• Trump's idea is not new Trump wants to tackle high prices with the "Most Favored Nation" system.
• He had already pushed this unsuccessfully during his first term in office.
• The idea is to link the reimbursement prices for medicines to the lowest price in wealthy comparator countries in order to reduce the high cost of medicines in the USA.
• This would force pharmaceutical companies to accept internationally comparable prices.
• The proposal was never implemented; there was legal and political resistance.
• In Trump's announcement, it now sounded as if it was not just about comparable prices in certain countries.
• Trump wrote that the USA would pay the same price as the country that pays the lowest price for a drug worldwide.
• Trump went on to emphasize: "Campaign contributions can work wonders - but not for me and not for the Republican Party."
• His government will now do the right thing - something the Democrats have been fighting for for years.
• The regulation of drugs was one of the central issues of Trump's predecessor in office, Joe Biden.
• Biden signed a major legislative package in 2022 that also authorized Medicare to negotiate certain drug prices.
• Biden's measure was considered a milestone.

Evonik $EVK (+0,37%)confirms annual target - operating profit recovers at the start of the year

• Better business with animal feed protein and continued cost-cutting efforts helped Evonik to increase profits in the first quarter.
• In addition, business with products for the paints and coatings industry and with active pharmaceutical ingredients improved.
• The annual profit target has been set. With sales almost unchanged at just under €3.8 billion, earnings before interest, taxes, depreciation and amortization (EBITDA) adjusted for special items rose by 7 percent year-on-year to €560 million, as the MDax-listed company announced on Monday.
• This is slightly less than analysts expected in terms of turnover, but more in terms of profit.
• The bottom line was 233 million euros, compared to 156 million a year ago.
• "Our efficiency efforts are taking effect.
• And this is also urgently needed in view of the renewed economic concerns," says CFO Maike Schuh.
• She and Evonik CEO Christian Kullmann are still targeting an operating profit (EBITDA) of between €2.0 billion and €2.3 billion for the current year, following a significant recovery to almost €2.07 billion in 2024.

Biotech company Formycon $FYB (-3,56%)starts the year with losses

• A decline in milestone payments and reimbursements for development services weighed on biosimilar manufacturer Formycon at the start of the year.
• However, neither is surprising, as projects are progressing.
• In addition, there is partial price pressure on sales in the USA.
• According to a statement on Monday, turnover in the first quarter fell by 70 percent year-on-year to EUR 5.3 million.
• Earnings before interest, taxes, depreciation and amortization (EBITDA) slipped from minus 5.5 to minus 13.2 million euros.
• The company confirmed its forecast for the current year.

Monday: Stock market dates, economic data, quarterly figures

Singapore stock exchange holiday

• ex-dividend of individual stocks
• Villeroy & Boch AG ex dividend € 0.90
• Draegerwerk AG & Co KGaA ex dividend € 2.03
• Draegerwerk AG & Co KGaA € 1.97
• DMG Mori AG € 1.03

• Quarterly figures / Company dates USA / Asia
• 07:00 Mazda quarterly figures
• 14:00 Fox Corp Quarterly figures

• Quarterly figures / Company dates Europe
• 07:00 Evonik Industries | Unicredit | Procredit | Formycon Quarterly figures
• 07:10 Hypoport quarterly figures
• 07:30 Salzgitter | Adesso | United Internet Quarterly figures
• 07:50 1&1 Quarterly figures
• 09:00 Ionos quarterly figures | Salzgitter analyst conference
• 10:00 Siltronic AGM
• 11:00 Evonik Analyst Conference
• 12:00 United Internet Analyst Conference
• 14:00 Hochtief quarterly figures
• 15:00 Formycon Conference Call

• Economic data

08:00 DE: Domestic Tourism March

15:00 EU: Eurogroup meeting

With my very conservative strategy, I find it really difficult not to gamble a little on the side 😀 With $FYB (-3,56%) I also came out with a good plus. Sometimes it's worth it after all. With $EU (-0,05%) we'll wait and see. But I think that both stocks will show a good reaction under Trump. Kind regards

Hello lovelies,

I would like to share my portfolio with you. With the sale of $MC (+0,36%) and a small profit, I'm getting closer to my goal - just the $IWDA (+1,34%) , $BTC (-0,04%) and gold - ever closer.

To be honest, I am very happy that these "old burdens" are gradually giving way to my portfolio. With $DHL (+1,58%) and $DG (-0,86%) I am still waiting for the sale until it is more or less sustainable for me. $FYB (-3,56%) will then also be sold with a plus.

And when I see that other people also want to go this way, I'm very happy :)

P.S. The $ACWI I'm saving for my little son

EQS-News: Formycon AG / Key word(s): Miscellaneous

Formycon to be included in the TecDAX of the German Stock Exchange

09.01.2025 / 15:30 CET/CEST

The issuer is solely responsible for the content of this announcement.

Press release // January 09, 2025

Formycon to be included in the TecDAX of Deutsche Börse

Formycon will be one of the top 30 listed technology stocks in future

Uplisting to the Prime Standard, promotion to the SDAX and successful business development boost the share's attractiveness

Inclusion in the TecDAX effective from January 13, 2025

Planegg-Martinsried - Formycon AG (FWB: FYB, Prime Standard, "Formycon") will be officially included in the TecDAX of Deutsche Börse as of January 13, 2025. This decision was announced today as part of an unscheduled index adjustment by Deutsche Börse. With its inclusion in the TecDAX, Formycon is one of the 30 largest listed technology companies in Germany - based on free float market capitalization and trading volume.

"We are extremely pleased that Formycon will now also be represented in the TecDAX just three weeks after its promotion to the SDAX. This milestone strengthens our position on the capital market and increases our visibility as one of the most important German technology stocks. Inclusion in these leading share indices underlines the success of our capital market strategy. Above all, however, it is an indicator of the outstanding performance that the entire Formycon team delivers every day as part of our successful growth strategy as a leading pure-play developer of biosimilars," says Enno Spillner, CFO of Formycon AG.

Since its initial listing in 2010, Formycon has consistently aligned itself with the requirements of the capital market and thus created a prerequisite for the extraordinarily positive business development in recent years and for the successful inclusion in the Prime Standard of Deutsche Börse in November 2024.

About Formycon:

Formycon AG (FWB: FYB) is a leading independent developer of high-quality biosimilars, follow-on products of biopharmaceutical drugs. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other important indication areas and covers almost the entire value chain from technical development and clinical trials to submission and regulatory approval. Formycon relies on strong, trustworthy and long-term partnerships worldwide for the commercialization of its biosimilars. With FYB201/Ranibizumab, Formycon already has a biosimilar on the market in Europe and the USA. Two further biosimilars, FYB202/Ustekinumab and FYB203/Aflibercept, have been approved by the FDA; FYB202 has also been approved in Europe and Canada. Three further biosimilar candidates are currently in development. With its biosimilars, Formycon is making an important contribution to giving as many patients as possible access to highly effective and affordable medicines.

Formycon AG is listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and has been included in the SDAX selection index since December 2024. Further information can be found at: www.formycon.com

About biosimilars:

Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection - including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare providers. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

Contact:

Sabrina Müller

Director Investor Relations & Corporate Communications

Formycon AG

Fraunhoferstr. 15

82152 Planegg-Martinsried

Germany

Phone: +49 (0) 89 - 86 46 67 149

Fax: + 49 (0) 89 - 86 46 67 110

Mail: sabrina.mueller@formycon.com

Disclaimer:

This release may contain forward-looking statements and information that are based on our current expectations and certain assumptions. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in the event of developments that differ from those anticipated. This document does not constitute an invitation to buy or sell Formycon shares. Furthermore, the company does not intend to offer Formycon shares to the public with this publication. This document and the information contained herein are not for distribution in the United States, Canada, Australia, Japan or any other jurisdiction in which the solicitation of an offer to buy or sell shares is prohibited. This publication is expressly not an invitation to purchase shares in the USA.

$FYB (-3,56%)

$FYB (-3,56%)

- Otulfi® has been approved by Health Canada for subcutaneous and intravenous formulations for the treatment of severe inflammatory diseases

- Health Canada joins FDA and European Commission in granting regulatory approval for FYB202

- The earliest date for commercialization of Otulfi® in Canada is set out in a confidential settlement agreement between Formycon, Fresenius Kabi and Johnson & Johnson signed in March 2024

Planegg-Martinsried, Germany - Formycon AG (FWB: FYB, Prime Standard, "Formycon") and its distribution partner Fresenius Kabi announce that Health Canada has issued a Notice of Compliance (NOC) for FYB202/Otulfi®1 (ustekinumab), a biosimilar to Stelara®2. This approval applies to subcutaneous and intravenous formulations for the treatment of adult patients with moderate to severe active Crohn's disease, moderate to severe active ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. Both the US Food and Drug Administration (FDA) and the European Commission had already granted marketing authorization for FYB202 in September 2024.

Let's see what happens...

Changes at Deutsche Börse:

The used car dealer Auto1 $AG1 (-0,68%) and the biotech company Evotec $EVT (+0,85%) return to the small cap index on 23.12.24 MDax of the German Stock Exchange. They will replace the metal recycler Befesa $BFSA (-0,43%) and the automotive and industrial supplier Stabilus $STM (-0,94%) which will be relegated to the small-cap index SDax, as announced by Deutsche Börse subsidiary ISS Stoxx on Wednesday evening.

Evotec was only forced to leave the MDax in September, but since then the shares have risen again in view of a possible sale of the company. Auto1, on the other hand, was previously listed on the MDax until spring 2022.

In addition, the SDAX also has three newcomers. The software company Nexus $NXU (+0,55%) the scientific publisher Springer Nature
$SPG (-0,72%) and the biosimilars specialist Formycon $FYB (-3,56%) .

On the other hand, the telecom equipment supplier Adtran Holdings
$ADTN (+0,94%) the office furniture mail order company Takkt
$TTK (+0,44%) and the hydrogen specialist Thyssenkrupp Nucera
$NCH2 (+0,35%) .

In the DAX there are no changes.

The changes will take effect on December 23 of this year.

Handelsblatt

Another depot update. Values are not quite correct but the reference value is. The crypto values are completely wrong but I have no idea where the entry price is (made kind of annoying at Coinbase). The best positions at the moment are $SOFI (+5,64%)
$FTNT (+1,99%)
$D05 (+0,63%) . The interesting values for me are $BNTX (-1,17%)
$FYB (-3,56%)
$SNOW (+0,9%)